{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:42:14Z","timestamp":1792208534621,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1245\/s10434-026-20319-7","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:06:39Z","timestamp":1785762399000},"page":"10100-10114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Chemoradiotherapy Versus Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis of Randomised Controlled Trials"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-1068","authenticated-orcid":false,"given":"Shahin","family":"Hajibandeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Hajibandeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameel","family":"Alfarah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Psica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Soulat","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby V. M.","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Marudanayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Sutcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Chatzizacharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"20319_CR1","first-page":"11","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11\u201330.","journal-title":"CA Cancer J Clin."},{"key":"20319_CR2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","volume":"15","author":"MA Tempero","year":"2017","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:1028\u201361.","journal-title":"J Natl Compr Canc Netw."},{"key":"20319_CR3","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.surg.2012.05.020","volume":"152","author":"CR Ferrone","year":"2012","unstructured":"Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, et al. Pancreatic ductal adenocarcinoma: long term survival does not equal cure. Surgery. 2012;152:S43\u20139.","journal-title":"Surgery."},{"key":"20319_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s11605-007-0384-8","volume":"12","author":"CR Ferrone","year":"2008","unstructured":"Ferrone CR, Brennan MF, Gonen M, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008;12:701\u20136.","journal-title":"J Gastrointest Surg."},{"issue":"4","key":"20319_CR5","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1007\/s00268-015-3353-5","volume":"40","author":"S Suzuki","year":"2016","unstructured":"Suzuki S, Furukawa T, Oshima N, Izumo W, Shimizu K, Yamamoto M. Original scientific reports: clinicopathological findings of remnant pancreatic cancers in survivors following curative resections of pancreatic cancers. World J Surg. 2016;40(4):974\u201381.","journal-title":"World J Surg."},{"issue":"6","key":"20319_CR6","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.surg.2023.11.027","volume":"175","author":"D Evans","year":"2024","unstructured":"Evans D, Ghassemi N, Hajibandeh S, Hajibandeh S, Romman S, Laing RW, Durkin D, Athwal TS. Meta-analysis of adjuvant chemotherapy versus no adjuvant chemotherapy for resected stage I pancreatic cancer. Surgery. 2024;175(6):1470\u20139.","journal-title":"Surgery."},{"key":"20319_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jso.23044","volume":"106","author":"KT Papalezova","year":"2012","unstructured":"Papalezova KT, Tyler DS, Blazer DG 3rd, Clary BM, Czito BG, Hurwitz HI, et al. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol. 2012;106:111\u20138.","journal-title":"J Surg Oncol."},{"key":"20319_CR8","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1002\/cam4.921","volume":"5","author":"MJ Bakens","year":"2016","unstructured":"Bakens MJ, van der Geest LG, van Putten M, van Laarhoven HW, Creemers GJ, Besselink MG, et al. The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis. Cancer Med. 2016;5:2825\u201331.","journal-title":"Cancer Med."},{"key":"20319_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/SLA.0000000000000378","volume":"260","author":"RP Merkow","year":"2014","unstructured":"Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260:372\u20137.","journal-title":"Ann Surg."},{"issue":"2","key":"20319_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","volume":"268","author":"JY Jang","year":"2018","unstructured":"Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial. Ann Surg. 2018;268(2):215\u201322.","journal-title":"Ann Surg."},{"issue":"16","key":"20319_CR11","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763\u201373.","journal-title":"J Clin Oncol."},{"issue":"4","key":"20319_CR12","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/jcm9041129","volume":"9","author":"JM Cloyd","year":"2020","unstructured":"Cloyd JM, Heh V, Pawlik TM, et al. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med. 2020;9(4):1129.","journal-title":"J Clin Med."},{"issue":"2","key":"20319_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","volume":"8","author":"P Ghaneh","year":"2023","unstructured":"Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):157\u201368.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"1","key":"20319_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12957-017-1240-2","volume":"15","author":"M Dhir","year":"2017","unstructured":"Dhir M, Malhotra GK, Sohal DPS, et al. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol. 2017;15(1):183.","journal-title":"World J Surg Oncol."},{"issue":"9","key":"20319_CR15","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/MPA.0000000000002147","volume":"51","author":"A Puleo","year":"2022","unstructured":"Puleo A, Malla M, Boone BA. Defining the optimal duration of neoadjuvant therapy for pancreatic ductal adenocarcinoma: time for a personalized approach? Pancreas. 2022;51(9):1083\u201391.","journal-title":"Pancreas."},{"key":"20319_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ."},{"issue":"2","key":"20319_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer."},{"key":"20319_CR18","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available at www.training.cochrane.org\/handbook. Accessed 4 May 2025."},{"issue":"7","key":"20319_CR19","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1245\/s10434-007-9384-x","volume":"14","author":"DH Palmer","year":"2007","unstructured":"Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007;14(7):2088\u201396.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"20319_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/jso.21527","volume":"101","author":"J Landry","year":"2010","unstructured":"Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB 3rd. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010;101(7):587\u201392.","journal-title":"J Surg Oncol."},{"issue":"5","key":"20319_CR21","first-page":"2377","volume":"34","author":"K Sahora","year":"2014","unstructured":"Sahora K, Schindl M, Kuehrer I, Eisenhut A, Werba G, Brostjan C, et al. A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer. Anticancer Res. 2014;34(5):2377\u201384.","journal-title":"Anticancer Res."},{"issue":"10","key":"20319_CR22","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","volume":"19","author":"R Casadei","year":"2015","unstructured":"Casadei R, Di Marco M, Ricci C, Santini D, Serra C, Calculli L, et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19(10):1802\u201312.","journal-title":"J Gastrointest Surg."},{"issue":"1","key":"20319_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00066-014-0737-7","volume":"191","author":"H Golcher","year":"2015","unstructured":"Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, et al. Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191(1):7\u201316.","journal-title":"Strahlenther Onkol."},{"issue":"6","key":"20319_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","volume":"3","author":"M Reni","year":"2018","unstructured":"Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2\u20133 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413\u201323.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"20319_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejca.2018.07.007","volume":"102","author":"M Reni","year":"2018","unstructured":"Reni M, Zanon S, Balzano G, Passoni P, Pircher C, Chiaravalli M, et al. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur J Cancer. 2018;102:95\u2013102.","journal-title":"Eur J Cancer."},{"issue":"4","key":"20319_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000668","volume":"5","author":"V Picozzi","year":"2020","unstructured":"Picozzi V, Alseidi A, Winter J, Pishvaian M, Mody K, Glaspy J, et al. Gemcitabine\/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open. 2020;5(4):e000668.","journal-title":"ESMO Open."},{"issue":"1","key":"20319_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00066-020-01680-2","volume":"197","author":"R Fietkau","year":"2021","unstructured":"Fietkau R, Gr\u00fctzmann R, Wittel UA, Croner RS, Jacobasch L, Neumann UP, et al. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007 trial. Strahlenther Onkol. 2021;197(1):8\u201318.","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"20319_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","volume":"6","author":"V Kunzmann","year":"2021","unstructured":"Kunzmann V, Siveke JT, Alg\u00fcl H, Goekkurt E, Siegler G, Martens U, Pancreatic Cancer Working Group (AIO-PAK), NEOLAP investigators, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(2):128\u201338.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"1","key":"20319_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/SLA.0000000000004669","volume":"275","author":"DB Hewitt","year":"2022","unstructured":"Hewitt DB, Nissen N, Hatoum H, Musher B, Seng J, Coveler AL, et al. A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-L (hyperacute-pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer. Ann Surg. 2022;275(1):45\u201353.","journal-title":"Ann Surg."},{"issue":"1","key":"20319_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","volume":"34","author":"T Seufferlein","year":"2023","unstructured":"Seufferlein T, Uhl W, Kornmann M, Alg\u00fcl H, Friess H, K\u00f6nig A, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2023;34(1):91\u2013100.","journal-title":"Ann Oncol."},{"issue":"5","key":"20319_CR31","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/SLA.0000000000004313","volume":"275","author":"JC van Dongen","year":"2022","unstructured":"van Dongen JC, Suker M, Versteijne E, Bonsing BA, Mieog JSD, de Vos-Geelen J, Dutch Pancreatic Cancer Group, et al. Surgical complications in a multicenter randomized trial comparing preoperative chemoradiotherapy and immediate surgery in Patients with Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial). Ann Surg. 2022;275(5):979\u201384.","journal-title":"Ann Surg."},{"issue":"6","key":"20319_CR32","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/SLA.0000000000005430","volume":"275","author":"J Yamaguchi","year":"2022","unstructured":"Yamaguchi J, Yokoyama Y, Fujii T, Yamada S, Takami H, Kawashima H, et al. Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM\/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Ann Surg. 2022;275(6):1043\u20139.","journal-title":"Ann Surg."},{"issue":"9","key":"20319_CR33","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","volume":"8","author":"MHG Katz","year":"2022","unstructured":"Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: The A021501 phase 2 randomized clinical trial. JAMA Oncol. 2022;8(9):1263\u201370.","journal-title":"JAMA Oncol."},{"issue":"12","key":"20319_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007586","volume":"11","author":"MHG Katz","year":"2023","unstructured":"Katz MHG, Petroni GR, Bauer T, Reilley MJ, Wolpin BM, Stucky CC, et al. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma. J Immunother Cancer. 2023;11(12):e007586.","journal-title":"J Immunother Cancer."},{"issue":"11","key":"20319_CR35","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/jhbp.1353","volume":"30","author":"T Sugiura","year":"2023","unstructured":"Sugiura T, Toyama H, Fukutomi A, Asakura H, Takeda Y, Yamamoto K, et al. Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04). J Hepatobiliary Pancreat Sci. 2023;30(11):1249\u201360.","journal-title":"J Hepatobiliary Pancreat Sci."},{"issue":"7","key":"20319_CR36","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1245\/s10434-024-15199-8","volume":"31","author":"D Yamada","year":"2024","unstructured":"Yamada D, Kobayashi S, Takahashi H, Iwagami Y, Akita H, Asukai K, et al. Results of a randomized clinical study of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (RCT, CSGO-HBP-015). Ann Surg Oncol. 2024;31(7):4621\u201333.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"20319_CR37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","volume":"9","author":"KJ Labori","year":"2024","unstructured":"Labori KJ, Bratlie SO, Andersson B, Angelsen JH, Bi\u00f6rserud C, Bj\u00f6rnsson B, et al. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2024;9(3):205\u201317.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"20319_CR38","doi-asserted-by":"crossref","unstructured":"Unno M, Motoi F, Matsuyama Y, Satoi S, Toyama H, Matsumoto I, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer: results of the randomized phase II\/III Prep-02\/JSAP05 trial. Ann Surg. 2025","DOI":"10.1097\/SLA.0000000000006730"},{"issue":"8","key":"20319_CR39","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/jnci\/djz073","volume":"111","author":"QP Janssen","year":"2019","unstructured":"Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111(8):782\u201394.","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"20319_CR40","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3390\/jcm11030812","volume":"11","author":"O De Simoni","year":"2022","unstructured":"De Simoni O, Scarpa M, Sold\u00e0 C, Bergamo F, Lonardi S, Fantin A, et al. Could total neoadjuvant therapy followed by surgical resection be the new standard of care in pancreatic cancer? A systematic review and meta-analysis. J Clin Med. 2022;11(3):812.","journal-title":"J Clin Med."},{"key":"20319_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2025.12.018","author":"S Hajibandeh","year":"2025","unstructured":"Hajibandeh S, Hajibandeh S, Raza SS, Bartlett DC, Dasari BVM, Chatzizacharias N, et al. Effect of duration of neoadjuvant therapy on pancreatic cancer outcomes: a systematic review and meta-analysis. HPB. 2025. https:\/\/doi.org\/10.1016\/j.hpb.2025.12.018.","journal-title":"HPB"},{"key":"20319_CR42","first-page":"100738","volume":"45","author":"MA Shouman","year":"2024","unstructured":"Shouman MA, Fuchs F, Walter F, Corradini S, Westphalen CB, Vornh\u00fclz M, et al. Stereotactic body radiotherapy for pancreatic cancer\u2014a systematic review of prospective data. Clin Transl Radiat Oncol. 2024;45:100738.","journal-title":"Clin Transl Radiat Oncol."},{"key":"20319_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102632","volume":"63","author":"J Dardare","year":"2026","unstructured":"Dardare J, Martz N, Witz A, Betz M, Michel C, Gilson P, et al. Radiotherapy in the management of PDAC, from past to present. Transl Oncol. 2026;63:102632.","journal-title":"Transl Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20319-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20319-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20319-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:23:38Z","timestamp":1792207418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20319-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["20319"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20319-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest or financial ties to disclose","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Considering the design of our study, ethical approval and consent were not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}